Drug intelligence / Profile preview

pruloglitin

Development stage: Unknown
Lead developer: CSPC Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

Pruloglitin (DBPR108) is a potent and selective small-molecule inhibitor of dipeptidyl peptidase-4 (DPP-4) developed by CSPC Pharmaceutical Group for the treatment of type 2 diabetes mellitus. Originally discovered by the National Health Research Institutes (NHRI) of Taiwan, pruloglitin works by preventing the degradation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This action enhances insulin secretion and suppresses glucagon release in a glucose-dependent manner, thereby improving glycemic control. Pruloglitin has undergone Phase 3 clinical evaluation in China as both a monotherapy and in fixed-dose combinations with metformin extended-release.

Other names: pruloglitin普鲁格列汀

Targets

DPP-4 (Dipeptidyl Peptidase-IV)

Beyond the preview

Go deeper on pruloglitin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pruloglitin.

Explore the full profile